IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 18.97

Change

+1.05 (+5.86)%

Market Cap

USD 0.12B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-09 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.80 (-0.59%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

-0.26 (-0.41%)

USD 2.70B
FXH First Trust Health Care AlphaD..

-0.13 (-0.13%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

+0.52 (+0.69%)

USD 0.18B
SBIO ALPS Medical Breakthroughs ETF

+0.53 (+2.04%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-1.74 (-1.81%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.06 (-0.24%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.42 (+0.78%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.42 (+2.59%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

-3.61 (-6.71%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.17% 19% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.17% 19% F 17% F
Trailing 12 Months  
Capital Gain -18.16% 14% F 20% F
Dividend Return 0.48% 44% F 7% C-
Total Return -17.68% 14% F 18% F
Trailing 5 Years  
Capital Gain -32.20% 10% F 12% F
Dividend Return 3.27% 53% F 6% D-
Total Return -28.93% 10% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -9.35% 5% F 7% C-
Dividend Return -8.79% 5% F 6% D-
Total Return 0.56% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 26.13% 14% F 39% F
Risk Adjusted Return -33.62% 5% F 8% B-
Market Capitalization 0.12B 60% D- 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.